BioParity.UFO / UAP research

2 sources for “Tumor-cell heterogeneity”

Results

PaperS7587

DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity

Benedict Anchang, Kara L. Davis, Harris G. Fienberg, Brian D. Williamson, Sean C. Bendall, Loukia G. Karacosta, Robert Tibshirani, Garry P. Nolan, Sylvia K. Plevritis. ebi.ac.uk. April 13, 2018.

DRUG-NEM ranks drug combinations using selected single-cell signaling responses. Its short-term surrogates and fixed-subpopulation assumptions limit interpretation. Repeated analyses are not new patients, and cell-line validation does not establish clinical benefit. The supplied main text is read; supporting information remains missing.

Supplied main text and mathematics read; apparatus partial
PaperS7593

Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry

Veronica D. Gonzalez, Nikolay Samusik, Tiffany J. Chen, Erica S. Savig, Nima Aghaeepour, David A. Quigley, Ying-Wen Huang, Valeria Giangarrà, Alexander D. Borowsky, Neil E. Hubbard, Shih-Yu Chen, Guojun Han, Alan Ashworth, Thomas J. Kipps, Jonathan S. Berek, Garry P. Nolan, Wendy J. Fantl. ebi.ac.uk. February 13, 2018.

Mass cytometry identifies tumor-cell subsets and outcome associations in a small ovarian-cancer cohort. Dominant and hybrid clusters did not individually correlate with relapse. Same-cohort marker selection and missing independent validation limit interpretation; cell-line response is not demonstrated patient benefit.

Supplied author manuscript read; figures and supplement missing

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach